会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明公开
    • 키나아제 억제제
    • 激酶抑制剂
    • KR1020130006417A
    • 2013-01-16
    • KR1020127011751
    • 2010-11-12
    • 제노스코주식회사 오스코텍
    • 이재규송호준고종성이희규김영삼김홍우장선화임선희최장식김중호김세원
    • C07D403/14A61K31/506A61P35/00
    • A61K31/505C07D403/04C07D403/14C07D405/14C07D417/14C07D487/08
    • PURPOSE: A novel protein kinase inhibitor is provided to treat cancer, autoimmune diseases, infection, cardiovascular diseases, neurodegenerative diseases. CONSTITUTION: A kinase inhibitor compound is denoted by chemical formula I. A pharmaceutical formulation contains the compound of chemical formula I with a pharmaceutically acceptable carrier, diluents, or excipient. A method for treating protein kinase-mediated diseases comprises a step of administering therapeutically effective amount of the compound of chemical formula I or pharmaceutically acceptable salt to a subject to be treated. The kinase inhibitor compound is used by intravenous, subcutaneous, colorectal, parenteral intramuscular, nasal, skin, topical, ear, oral, ocular, or sublingual administration or inhalation. A method for suppressing SYK, PYK2, FAK, ZAP70, PIM1, FLT3, RET, JAK2, JAK3, LRRK2, LRRK2(G2019S), ABL1(T315I), AURKB, AXL, FLT3, KIT, KIT(D816V), KIT(V559D,T670I), MKNK2, MLK1, PDGFRB, PLK3, RET, SNARK, SRPK3, TAK1, or TYK2 signal transduction in the subject comprises a step of administering effective amount of the compound of chemical formula I.
    • 目的:提供一种新的蛋白激酶抑制剂,用于治疗癌症,自身免疫疾病,感染,心血管疾病,神经变性疾病。 构成:激酶抑制剂化合物由化学式I表示。药物制剂含有化学式I化合物和药学上可接受的载体,稀释剂或赋形剂。 用于治疗蛋白激酶介导的疾病的方法包括向受治疗对象施用治疗有效量的化学式I化合物或其药学上可接受的盐的步骤。 激酶抑制剂化合物通过静脉内,皮下,结肠直肠,肠胃外,肌内,鼻腔,皮肤,局部,耳朵,口服,眼部或舌下给药或吸入使用。 一种抑制SYK,PYK2,FAK,ZAP70,PIM1,FLT3,RET,JAK2,JAK3,LRRK2,LRRK2(G2019S),ABL1(T315I),AURKB,AXL,FLT3,KIT,KIT(D816V),KIT(V559D ,T670I),MKNK2,MLK1,PDGFRB,PLK3,RET,SNARK,SRPK3,TAK1或TYK2信号转导的方法包括施用有效量的化学式I的化合物的步骤。